Novavax, Inc. (NASDAQ:NVAX) Stock Has Consensus Price Target of $12.33

Key Points

• Novavax has a consensus “Hold” rating from 10 analysts, with five buys, two holds and three sells. The average 12-month price target is $12.33 versus the stock’s reported price of $10.47.
• Institutional investors own 53.04% of Novavax, with several large funds establishing or increasing positions. The company’s latest quarterly results beat estimates, though revenue fell 76.2% year over year and profitability remained negative.
• A $125 million milestone payment from Sanofi provides a near-term cash catalyst and supports the potential of Novavax’s combination flu-COVID vaccine partnership, while analysts warn of possible earnings weakness ahead of the upcoming results.

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has earned an average recommendation of "Hold" from the ten research firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $12.33.

Several research firms have recently commented on NVAX. Weiss Ratings restated a "sell (d)" rating on shares of Novavax in a research report on Tuesday, August 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Novavax in a research report on Tuesday. Citigroup reaffirmed a "sell" rating and issued a $8.00 price target (up from $7.00) on shares of Novavax in a research report on Thursday, October 15th. Zacks Research cut Novavax from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised shares of Novavax from a "sell" rating to a "hold" rating in a research report on Saturday, September 12th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new position in Novavax in the second quarter valued at about $8,004,000. Edgestream Partners L.P. acquired a new stake in shares of Novavax during the 1st quarter valued at approximately $4,234,000. Renaissance Technologies LLC purchased a new stake in shares of Novavax during the 1st quarter worth approximately $4,049,000. Squarepoint Ops LLC purchased a new stake in shares of Novavax during the 2nd quarter worth approximately $1,258,000. Finally, First Trust Advisors LP grew its holdings in shares of Novavax by 37.7% in the 1st quarter. First Trust Advisors LP now owns 409,328 shares of the biopharmaceutical company's stock worth $3,332,000 after acquiring an additional 112,009 shares during the period. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Price Performance

Novavax stock opened at $10.47 on Friday. The stock has a market capitalization of $1.73 billion, a PE ratio of -6.89 and a beta of 2.44. Novavax has a 12 month low of $6.20 and a 12 month high of $13.39. The business has a 50 day simple moving average of $10.43 and a 200-day simple moving average of $9.29.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. The company had revenue of $56.70 million during the quarter, compared to analysts' expectations of $52.51 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. Novavax's revenue was down 76.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 EPS. On average, equities research analysts anticipate that Novavax will post -0.50 EPS for the current fiscal year.

Key Novavax News

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Sanofi milestone payment provides an immediate catalyst. Novavax earned a $125 million payment after Sanofi dosed the fifth patient in a Phase 3 European trial of an influenza-COVID-19 combination vaccine using Novavax’s Nuvaxovid. The payment strengthens Novavax’s cash position and validates the commercial potential of its Sanofi partnership. Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
• Positive Sentiment: Combination-vaccine opportunity could create additional long-term value. Sanofi’s Phase 3 study is testing Nuvaxovid alongside its high-dose flu vaccine in adults aged 60 and older. Positive results could lead to additional milestones and future royalty opportunities for Novavax in the combined flu and COVID-19 market, which the company estimates exceeds $10 billion. Novavax Earns $125 Million Milestone From Sanofi’s Phase 3 Vaccine Trial in Europe
• Neutral Sentiment: Third-quarter results are scheduled for November 5. Novavax plans to release its financial results before the U.S. market opens and hold a conference call at 8:30 a.m. ET. The report may provide updates on operating performance, cash resources, vaccine demand and the Sanofi collaboration. Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
• Negative Sentiment: Analysts are flagging potential earnings weakness ahead of the report. A Zacks analysis says NVAX lacks the usual combination of earnings and revenue-estimate trends associated with a likely beat, raising the risk of a disappointing third-quarter result and increased volatility around the release. Novavax May Report Negative Earnings

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax's principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.